Plain-English translation of NCT06982729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing a new medication called for primary membranous nephropathy, a kidney disease where your kidneys leak too much protein into your urine. The trial has two parts: the first part tests how safe the medication is and finds the best dose, while the second part looks at whether the medication actually works to reduce protein leakage. Researchers will closely monitor your kidney function and health throughout the study.
Primary membranous nephropathy can lead to kidney failure if not treated, and current treatment options don't work well for everyone. This trial is exploring whether this new treatment might offer patients a better way to control their disease and protect their kidneys.
You likely qualify if…
You likely don't qualify if…
In the first part of the trial, you would receive doses of the medication through an IV infusion and have your safety carefully monitored as the dose gradually increases. In the second part, participants receive one of two doses to see which works best. Throughout the study, you'll have regular clinic visits for blood tests, urine tests, and kidney function checks to make sure the medication is safe and see if it's reducing protein leakage in your urine.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Excyte Biopharma Ltd
Enrollment target
~72 participants
Started
March 2025
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Minghui Zhao, M.D.
Peking University First Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.